Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PBRM1 loss |
Therapy | PRT1419 + Sunitinib |
Indication/Tumor Type | lung cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PBRM1 loss | lung cancer | sensitive | PRT1419 + Sunitinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of PRT1419 and Sutent (sunitinib) inhibited tumor growth and tumor re-growth in a lung cancer cell line xenograft model with loss of PBRM1 (PMID: 38371625). | 38371625 |
PubMed Id | Reference Title | Details |
---|---|---|
(38371625) | PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer. | Full reference... |